{"id":274115,"date":"2026-09-28T11:17:31","date_gmt":"2026-09-28T05:47:31","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=274115"},"modified":"2026-09-28T11:17:31","modified_gmt":"2026-09-28T05:47:31","slug":"lupin-share-price-us-fda-approval","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lupin-share-price-us-fda-approval\/","title":{"rendered":"Lupin Wins Tentative US FDA Approval for a Liquid Version of Apixaban, Yet the Stock Slips With the Market"},"content":{"rendered":"

Lupin Rs 2,066.70, down 1.21% (28 Sep, 11 AM). 52-week range Rs 1,900 to 2,529.50. RSI 43.1. Q1 FY27 profit around Rs 1,417 crore. P\/E 17.22 against industry 38.42.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Lupin share price was Rs 2,066.70 at 11 AM on 28 September 2026, down 1.21 percent, even after the company received tentative US FDA approval for Apixaban Oral Suspension 1.25 mg\/mL. The approval is tentative, so Lupin cannot sell the product in the United States until the FDA grants final approval. The stock trades below its 20-day average of Rs 2,106.58 while the Sensex is down more than 1.3 percent, so the news has not yet shown up in the price. Once final approval arrives, Lupin plans to manufacture the product at its Somerset facility in New Jersey.<\/p>\n<\/div>\n

Lupin Limited said on Monday that the US Food and Drug Administration has tentatively approved its New Drug Application for Apixaban Oral Suspension 1.25 mg\/mL under the 505(b)(2) pathway. Apixaban is the active ingredient in Bristol Myers Squibb’s blood thinner Eliquis, and Lupin’s version is an oral liquid for adults on anticoagulation therapy who find tablets hard to swallow.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

The market did not reward the announcement. Lupin traded between Rs 2,062.80 and Rs 2,098.60 by 11 AM against a previous close of Rs 2,092. This article explains what the approval means, what it does not, and where the Lupin share price stands on the charts and on valuation.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n